New strategies for studying circulating protein biomarkers using antibody microarrays in clinical studies

Gumanova N.G.

doi:https://doi.org/10.17116/profmed202427021119

Close metadata

Recommended articles:

Post-exposure prophylaxis of influenza and ARVI. Results of a double-blind, placebo-controlled clinical trial of Meglumine acridone acetate and its pharmacoeconomic rationale. Russian Journal of Preventive Medicine. 2025;(4):57-66

Study of the consistency and validity of the Russian version Adult Eating Behaviour Questionnaire. Russian Journal of Preventive Medicine. 2025;(8):89-95

L-lysine aescinate for back pain: a systematic review. Russian Journal of Pain. 2024;(4):46-54

Development of a method for moxonidine quantification in blood and urine by high-performance liquid chromatography with tandem mass-selective detection. Forensic Medical Expertise. 2024;(6):42-47

Abstract:

The review addresses the latest achievements and developments in protein biomarkers, made using antibody-based multiplex systems, namely microarray technology, which help to understand the molecular mechanism of diseases better and identify biomarkers specific to diseases, their stages, severity, and prognosis of therapy outcomes. We analyzed essential aspects related to the design of clinical trials using microarrays to select candidate markers for further study. This review aims to summarize international and Russian experience using antibody-based microarray proteomic assay technology to study protein biomarkers in clinical trials. The literature search was done in the PubMed and Russian Science Index databases. Also, the review includes published data from our own research cited in the PubMed and Science Index databases. Due to the novelty of microarray technologies, the earliest paper relevant to the topic was published in 2008. If the full text of the article was not available, abstracts were not considered for analysis.

Keywords:

antibody-based microarray

microarray technology

protein markers

clinical studies

validation

Authors:

Gumanova N.G.

National Medical Research Center for Therapy and Preventive Medicine

ORCID: 0000-0002-6108-3538

Received:

13.07.2023

Accepted:

25.09.2023

Close metadata

References:

Chen H, Zhu Z, Zhu Y, et al. Pathway mapping and development of disease-specific biomarkers: protein-based network biomarkers. Journal of Cellular and Molecular Medicine. 2015;19(2):297-314. https://doi.org/10.1111/jcmm.12447
Ekins RP, Chu FW. Multianalyte microspot immunoassay — microanalytical «compact disk» of the future. Clinical Chemistry. 1991;37(11):1955-1967.
Gumanova NG. Valid tumor markers: screening, diagnosis, prognosis of cancer. Profilakticheskaja meditsina. 2022;25(6):108-116. (In Russ.). https://doi.org/10.17116/profmed202225061108
Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clinical Chemistry. 2010;56(2):177-185. https://doi.org/10.1373/clinchem.2009.126706
Scaros O, Fisler R. Biomarker technology roundup: from discovery to clinical applications, a broad set of tools is required to translate from the lab to the clinic. BioTechniques. 2005;(Suppl):30-32. https://doi.org/10.2144/05384su01
Plasma Proteome Database (PPD). Accessed December 15, 2023. https://www.plasmaproteomedatabase.org
Deutsch EW, Omenn GS, Sun Z, et al. Advances and Utility of the Human Plasma Proteome. Journal of Proteome Research. 2021;20(12):5241-5263. https://doi.org/10.1021/acs.jproteome.1c00657
Gallego-Delgado J, Lazaro A, Osende JI, et al. Proteomic approach in the search of new cardiovascular biomarkers. Kidney International. Supplement. 2005;(99):S103-S107. https://doi.org/10.1111/j.1523-1755.2005.09919.x
Gumanova NG, Klimushina MV, Bogdanova NL, et al. Valid cardiac biochemical markers. Part II. Kardiovaskulyarnaya terapiya i profilaktika. 2020; 19(5):2588. (In Russ.). https://doi.org/10.15829/1728-8800-2020-2588
Dubois E, Fertin M, Burdese J, et al. Cardiovascular proteomics: translational studies to develop novel biomarkers in heart failure and left ventricular remodeling. Proteomics. Clinical Applications. 2011;5(1-2):57-66. https://doi.org/10.1002/prca.201000056
Banfi C, Brioschi M, Barcella S, et al. Oxidized proteins in plasma of patients with heart failure: role in endothelial damage. European Journal of Heart Failure. 2008;10(3):244-251. https://doi.org/10.1016/j.ejheart.2008.01.016
Tan HT, Ling LH, Dolor-Torres MC, et al. Proteomics discovery of biomarkers for mitral regurgitation caused by mitral valve prolapse. Journal of Proteomics. 2013;94:337-345. https://doi.org/10.1016/j.jprot.2013.10.009
de Hoog VC, Timmers L, Schoneveld AH, et al. Serum extracellular vesicle protein levels are associated with acute coronary syndrome. European Heart Journal. Acute Cardiovascular Care. 2013;2(1):53-60. https://doi.org/10.1177/2048872612471212
Chan MY, Lin M, Lucas J, et al. Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thrombosis and Haemostasis. 2012;108(6):1180-1191. https://doi.org/10.1160/TH12-05-0310
Yin X, Subramanian S, Hwang SJ, et al. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arteriosclerosis, Thrombosis, and Vascular Biology. 2014;34(4):939-945. https://doi.org/10.1161/ATVBAHA.113.302918
Haas B, Serchi T, Wagner DR, et al. Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker. Journal of Proteomics. 2011;75(1):229-236. https://doi.org/10.1016/j.jprot.2011.06.028
Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41. https://doi.org/10.1161/01.str.24.1.35
Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clinical Chemistry. 2008;54(10):1608-1616. https://doi.org/10.1373/clinchem.2008.108175
Dunn WB, Broadhurst DI, Atherton HJ, et al. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chemical Society Reviews. 2011;40(1):387-426. https://doi.org/10.1039/b906712b
Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Molecular and Cellular Proteomics: MCP. 2006;5(4):573-588. https://doi.org/10.1074/mcp.M500331-MCP200
Haab BB. Antibody arrays in cancer research. Molecular & Cellular Proteomics: MCP. 2005;4(4):377-383. https://doi.org/10.1074/mcp.M500010-MCP200
Guergova-Kuras M, Kurucz I, Hempel W, et al. Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Molecular and Cellular Proteomics. 2011;10(12):M111.010298. https://doi.org/10.1074/mcp.M111.010298
Knezevic V, Leethanakul C, Bichsel VE, et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics. 2001;1(10):1271-1278. https://doi.org/10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO;2-6;3.0.CO;2-6
Don ES, Tarasov AV, Epshtein OI, Tarasov SA. The biomarkers in medicine: search, choice, study and validation. Klinicheskaya laboratornaya diagnostika. 2017;62(1):52-59. (In Russ.).
Bogdanova NL, Gumanova NG, Metelskaya VA, et al. Rational choice of the biochemical marker in a cohort study. Profilakticheskaya meditsina. 2022;25(11):68-75. (In Russ.). https://doi.org/10.17116/profmed20222511168
Gumanova NG, Klimushina MV, Metelskaya VA, Boitsov SA. The Possibilities of the application technology of protein microarray (microchip) for analysis of protein composition of blood serum. Klinicheskaya laboratornaya diagnoslika. 2015;60(10):16-21. (In Russ.).
Klimushina MV, Gumanova NG, Metelskaya VA. Direct labeling of serum proteins by fluorescent dye for antibody microarray. Biochemical and Biophysical Research Communications. 2017;486(3):824-826. https://doi.org/10.1016/j.bbrc.2017.03.136
Full Moon Biosystems; Signaling Explorer Antibody Array. Accessed December 15, 2023. https://www.fullmoonbio.com/product/signaling-explorer-antibody-array
Gumanova NG, Vasilyev DK, Bogdanova NL, et al. Application of an antibody microarray for serum protein profiling of coronary artery stenosis. Biochemical and Biophysical Research Communications. 2022;631:55-63. https://doi.org/10.1016/j.bbrc.2022.09.053
General Sandwich ELISA Protocol. Accessed December 15, 2023. https://www.thermofisher.com/ru/ru/home/references/protocols/cell-and-tissue-analysis/elisa-protocol/general-elisa-protocol.html
Gumanova NG, Zlobina PD, Bogdanova NL, et al. Associations of adenovirus-reactive immunoglobulins with atrial fibrillation and body mass index. Frontiers in Cardiovascular Medicine. 2023;10:1190051. https://doi.org/10.3389/fcvm.2023.1190051
Gumanova NG, Bogdanova NL, Metelskaya VA. Proteomic biomarker evaluation using antibody microarrays: association between analytical methods such as microarray and ELISA. Laboratory Medicine. 2023:lmad083. Online ahead of print. https://doi.org/10.1093/labmed/lmad083